Novartis Q4 Results

↓ ↑ Content LeqvioⓇ - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials > Cardiovascular, Renal and Metabolic Immunology Neuroscience Oncology Other Global Health Abbreviations References NCT04652726 ORION-16 (CKJX839C12301) Hyperlipidemia, pediatrics Indication Phase Phase 3 Patients 141 Primary Outcome Measures Arms Intervention Target Patients Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630 Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) Readout Milestone(s) 2025 Publication TBD □ NOVARTIS Reimagining Medicine Leqvio® - siRNA (regulation of LDL-C) NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Indication Phase Phase 3 Patients 13 Primary Outcome Measures Arms Intervention Target Patients Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630. Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) Readout Milestone(s) 2025 Publication TBD Novartis Q4 Results | January 31, 2024 51

View entire presentation